Table 2.
Characteristics of the pathologic node-negative patients’ group according to lymph node dissection number.
| Variable | <10 Nodes (n = 69) No. (%) |
≥10 Nodes (n = 216) No. (%) |
Total (n = 285) No. (%) |
p-Value |
|---|---|---|---|---|
| Age (years) | 45.6 ± 10.1 | 45.4 ± 9.7 | 45.5 ± 9.7 | 0.867 |
| BMI | 23.5 ± 2.9 | 24.2 ± 3.4 | 24.0 ± 3.3 | 0.123 |
| Type of surgery | 0.697 | |||
| Conserving surgery | 41 (59.4) | 134 (62.0) | 175 (61.4) | |
| Mastectomy | 28 (40.6) | 82 (37.9) | 110 (38.6) | |
| ER status | 0.684 | |||
| Negative | 45 (65.2) | 135 (62.5) | 180 (63.2) | |
| Positive | 24 (34.8) | 81 (37.5) | 105 (36.8) | |
| PR status | 0.997 | |||
| Negative | 49 (71.0) | 153 (70.8) | 202 (70.1) | |
| Positive | 20 (29.0) | 63 (29.2) | 83 (29.1) | |
| HER2 status | 0.997 | |||
| Negative | 40 (58.0) | 125 (57.9) | 165 (57.9) | |
| Positive | 29 (42.0) | 91 (42.1) | 120 (42.1) | |
| Pathologic tumor stage | 0.854 | |||
| ypT0-is | 30 (43.5) | 93 (43.0) | 123 (43.2) | |
| ypT1 | 25 (36.2) | 68 (31.5) | 93 (32.6) | |
| ypT2 | 11 (15.9) | 38 (17.6) | 49 (17.2) | |
| ypT3 | 3 (4.3) | 16 (7.4) | 19 (6.7) | |
| ypT4 | 0 (0.0) | 1 (0.5) | 1 (0.3) | |
| Radiotherapy | 0.324 | |||
| Absent | 10 (14.5) | 22 (10.2) | 32 (11.2) | |
| Present | 59 (85.5) | 194 (89.8) | 253 (88.8) |
BMI = body mass index; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor-2.